Quote Request
In Vivo Model Development for Pancreatic Cancer
Alfa Cytology has extensive experience in pancreatic cancer (PC) therapy development, covering all stages from target identification to preclinical validation. We use the most effective combination of tools to identify promising therapies, and design goal-oriented studies by selecting the most appropriate from a wide range of well-defined tumor models.
Introduction to Animal Model
Cancer models are in vivo mouse models used to test and support the development of novel anti-cancer therapies. Mouse homologous or human allogeneic tumor models are commonly used and can be used to test the efficacy of cancer therapies.
Fig. 1 Overview of different in
vivo PC models highlighting characteristics for each model. (Heinrich MA.; et al., 2021)
The best cancer model choice depends on the specific anti-cancer therapy. For example, syngeneic or humanized models are the best choice for immunotherapy. A humanized mouse tumor model is most advantageous if the therapy includes human targets that do not cross-react with other species. Patient-derived xenograft tumor models retain tumor heterogeneity and other characteristics and can be used as true transformation models.
Our Services
Alfa Cytology combines cancer models with appropriate translational tools, such as ELISpot, flow cytometry, imaging, gene expression analysis, and more to develop the most effective and relevant study design and screening methods to identify promising therapies and optimize prime drug candidates.
Xenografted mouse models with human cells play an important role in the screening and evaluation of novel anti-cancer testing therapies.
- CDX models
- PDX models
Syngeneic mouse models of immune-capable mice provide a comprehensive and effective method for in vivo efficacy studies. Alfa Cytology provides syngeneic mouse models.
- Subcutaneous formats
- Orthotopic formats
Each of the humanized mouse model platforms offered by Alfa Cytology is specifically designed for pancreatic cancer research.
- Humanized CD34+ (huCD34) models
- Humanized PBMC (huPBMC) models
- Knock-in humanized models
Alfa Cytology provides high-quality genetically engineered models.
- Transgenes
- Targeted mutations
- Retroviral mutations
- Proviral mutations
- Chemically induced mutations
Resistance to cancer drugs remains a major challenge for oncology. Alfa Cytology provides drug-resistant models to investigate new mechanisms of resistance and test new strategies and therapies.
- Gene editing drug resistance model
- Selective drug pressure resistance model
Metastatic models remain an essential part of the oncology toolkit. Alfa Cytology offers multiple preclinical metastatic models to fit multiple pancreatic cancer metastasis questions.
- Liver metastasis
- Bone metastasis
- Lung metastasis
- Brain metastasis
Why Choose Us?
Customized solution
Highly-experienced expert team
Variety of preclinical models
Quick turnaround time
Worldwide service
It is well known that selecting the right animal model is critical to the success of pancreatic cancer research. Alfa Cytology is committed to providing high-quality animal models for your research. From gene editing and pancreatic cancer-specific models to surgically modified animals, you can trust us to be an integral part of your research project. Please feel free to contact us.
Reference
- Heinrich, MA., et al. Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models. Adv Drug Deliv Rev. 2021;174:265-293. doi:10.1016/j.addr.2021.04.018
